埃格列净 T15244

Product Introduction
Bioactivity


英文名: Ertugliflozin L-pyroglutamic acid

描述: Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) 是一种特异性和口服活性的 hSGLT2 抑制剂，IC50 为 0.877 nM。 Ertugliflozin L-pyroglutamic acid 可用于治疗 2 型糖尿病的研究。

体外活性: Ertugliflozin L-pyroglutamic acid 展现出对SGLT2而非SGLT[2]的选择性高出2000倍以上。

体内活性: The oral administration of Ertugliflozin L-pyroglutamic to rats acid showed concentration-dependent glucosuria[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 125 mg/mL (220.85 mM)


关键字: SGLT | inhibit | Ertugliflozin L-pyroglutamic acid | Sodium-dependent glucose cotransporters | Inhibitor | Ertugliflozin L pyroglutamic acid | Ertugliflozin Lpyroglutamic acid

相关产品: Tofogliflozin (hydrate) | Ipragliflozin | SGL5213 | Phloretin | O-Desethyl Dapagliflozin | Enavogliflozin | Licogliflozin | Leachianone A | Picraline | Sotagliflozin

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | GPCR Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | EMA Approved Drug Library

埃格列净 T15244信息由TargetMol中国为您提供，如您想了解更多关于埃格列净 T15244报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途